Search
Breast Cancer Clinical Trials in Orlando, FL
A listing of 33 Breast Cancer clinical trials in Orlando, FL actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 12 of 33
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Breast Cancer
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
The city of Orlando, Florida, currently has 33 active clinical trials seeking participants for Breast Cancer research studies.
Featured Therapy
Unique Treatment for High Blood Pressure
Worried about high blood pressure? Think beyond typical high blood pressure treatments.
People who may be candidates for this procedure:
ā¢ Are at least 18 years old
ā¢ Have been unable to manage their high blood pressure with medications or lifestyle changes aloneĀ¹
Learn about a safe and effective procedure that may help reduce high blood pressure. See if you qualify today.
Ā¹ Kandzari DE, et al. J Am Coll Cardiol. Nov 7, 2023;82(19):1809-1823.
People who may be candidates for this procedure:
ā¢ Are at least 18 years old
ā¢ Have been unable to manage their high blood pressure with medications or lifestyle changes aloneĀ¹
Learn about a safe and effective procedure that may help reduce high blood pressure. See if you qualify today.
Ā¹ Kandzari DE, et al. J Am Coll Cardiol. Nov 7, 2023;82(19):1809-1823.
Conditions:
High Blood Pressure
High Blood Pressure (& [Essential Hypertension])
High Blood Pressure (Hypertension).
Hypertension
Essential Hypertension
Featured Offer
Discover Affordable Semaglutide Providers
We Checked the Checkout Page on Every Semaglutide Provider. Here's What We Found.
There's a big difference between the price on a landing page and what you actually pay. We went all the way through checkout so you know exactly what to expect.
š 5 providers ranked by true monthly cost
šµ Options starting as low as $149/month
š„ Only licensed providers using FDA-registered pharmacies
ā Real Trustpilot scores included ā including the ones with mixed reviews
š Includes cancellation policy warnings so you don't get stuck
There's a big difference between the price on a landing page and what you actually pay. We went all the way through checkout so you know exactly what to expect.
š 5 providers ranked by true monthly cost
šµ Options starting as low as $149/month
š„ Only licensed providers using FDA-registered pharmacies
ā Real Trustpilot scores included ā including the ones with mixed reviews
š Includes cancellation policy warnings so you don't get stuck
Conditions:
Weight Loss
Morbid Obesity
Featured Trial
Healthy Participants Needed (Colonoscopy + Cancer Screening)
Recruiting
Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
Conditions:
Healthy
Healthy Volunteers
Healthy Subjects
Healthy Volunteer
Healthy Participants
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Conditions:
Healthy
Healthy Volunteer Study
Featured Trial
Discover Clinical Trials In Your Area (Compensation Provided)
Recruiting
Clinical trials in your area are actively enrolling ā and they compensate you for your time. Finding the right one has never been easier.
- Matched to trials in your zip code
- Compensation for time & travel
- Free or low-cost treatments available
- No experience or medical background needed
- Takes just 30 seconds to see if you qualify
- Matched to trials in your zip code
- Compensation for time & travel
- Free or low-cost treatments available
- No experience or medical background needed
- Takes just 30 seconds to see if you qualify
Conditions:
Healthy
Healthy Volunteers
Featured Trial
Type 2 Diabetes (T2DM) Clinical Study
Recruiting
A clinical study for people that suffer with Type 2 Diabetes (T2DM)
Conditions:
Type 2 Diabetes (T2DM)
Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
Recruiting
The primary objective of the study is to measure efficacy of saruparib (AZD5305) plus camizestrant compared with physician's choice CDK4/6i plus ET in patients with BRCA1, BRCA2, or PALB2m, HR-positive, HER2-negative (defined as IHC 0, 1+, 2+/ ISH non-amplified) advanced breast cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/22/2025
Locations: Research Site, Orlando, Florida
Conditions: Advanced Breast Cancer
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Recruiting
A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or metastatic, relapsed or refractory carcinomas
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: Dren Investigational Site, Orlando, Florida
Conditions: Triple Negative Breast Cancer, HER2-negative Breast Cancer, Non Small Cell Lung Cancer, Cervical Cancer, Castrate Resistant Prostate Cancer, Pancreatic Ductal Adenocarcinoma, Head-and-neck Squamous Cell Carcinoma, Endometrial Cancer, Ovarian Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, Urothelial Carcinoma
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Recruiting
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after surgery and pre-surgical treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: Orlando Health, Orlando, Florida
Conditions: Triple Negative Breast Cancer
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Recruiting
The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ overexpression.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2025
Locations: Florida Cancer Specialists - Lake Nona, Orlando, Florida
Conditions: Breast Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Cancer, Colorectal Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Ovarian Cancer, Urothelial Carcinoma, Salivary Gland Cancer, Pancreatic Cancer, HER-2 Protein Overexpression
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Recruiting
The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/05/2025
Locations: AdventHealth Orlando Infusion Center, Orlando, Florida
Conditions: Breast Cancer
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Recruiting
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, tolerability and preliminary efficacy of multiple dose levels of rezatapopt as monotherapy and in Phase 1b in combination with pembrolizumab.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
08/04/2025
Locations: Advent Health, Orlando, Florida
Conditions: Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer, Gall Bladder Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Small Cell Lung Carcinoma, NSCLC, NSCLC (non-small Cell Lung Cancer), SCLC, Non-Small Cell Lung Carcinoma, Triple Negative Breast Cancer, TNBC, HER2+ Breast Cancer, Non-Small Cell Lung Cancer, ER/PR Positive Breast Cancer, HER2- Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, ER/PR(+), Her2(-) Breast Cancer
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Recruiting
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2025
Locations: Sara Cannon Research Institute Lake Nona, Orlando, Florida
Conditions: Non Small Cell Lung Cancer, Lung Cancer, Breast Cancer, Esophageal Cancer, Small Cell Lung Cancer, Nasopharyngeal Cancer, Head and Neck Squamous Cell Carcinoma
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Recruiting
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.
Gender:
ALL
Ages:
Between 50 years and 70 years
Trial Updated:
08/01/2025
Locations: AdventHealth Orlando, Orlando, Florida +1 locations
Conditions: Stage I Breast Cancer
Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer
Recruiting
This Phase III trial compares the recurrence-free interval (RFI) among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the standard of care.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
08/01/2025
Locations: Orlando Health Cancer Institute, Orlando, Florida
Conditions: HER2-positive Breast Cancer
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Recruiting
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Gender:
FEMALE
Ages:
Between 18 years and 60 years
Trial Updated:
08/01/2025
Locations: AdventHealth Orlando, Orlando, Florida +1 locations
Conditions: Breast Cancer
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
Recruiting
This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor \[Retifanlimab\], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metastatic or locally recurrent breast cancer (aMBC) patients with no approved alternative therapies available.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: Advent Health - Orlando, Orlando, Florida
Conditions: Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm, Breast Cancer Metastatic, End Stage Cancer
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
Recruiting
The purpose of this study is to find out whether the study drug, LY4101174, is safe, tolerable and effective in participants with select advanced or metastatic solid tumors. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: AdventHealth Orlando, Orlando, Florida
Conditions: Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Pancreatic Cancer, Ovarian Cancer, Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Renal Pelvis Cancer, Bladder Cancer
1 - 12 of 33